-
1
-
-
0024453308
-
Identification of the cystic fibrosis gene: Chromosome walking and jumping
-
Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-1065.
-
(1989)
Science
, vol.245
, Issue.4922
, pp. 1059-1065
-
-
Rommens, J.M.1
Iannuzzi, M.C.2
Kerem, B.3
-
2
-
-
0027395872
-
The changing epidemiology of cystic fibrosis
-
FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1-9.
-
(1993)
J Pediatr
, vol.122
, Issue.1
, pp. 1-9
-
-
Fitzsimmons, S.C.1
-
3
-
-
79952643169
-
-
Cystic Fibrosis Foundation Patient Registry, Bethesda, MD: Cystic Fibrosis Foundation 2009
-
Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2008. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
-
Annual Data Report 2008
-
-
-
4
-
-
0036320272
-
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
-
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
-
(2002)
Pediatr Pulmonol
, vol.34
, Issue.2
, pp. 91-100
-
-
Emerson, J.1
Rosenfeld, M.2
McNamara, S.3
Ramsey, B.4
Gibson, R.L.5
-
5
-
-
0034764166
-
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
-
Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356-366.
-
(2001)
Pediatr Pulmonol
, vol.32
, Issue.5
, pp. 356-366
-
-
Rosenfeld, M.1
Gibson, R.L.2
McNamara, S.3
-
6
-
-
0142043977
-
Pathophysiology and management of pulmonary infections in cystic fibrosis
-
Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-951.
-
(2003)
Am J Respir Crit Care Med
, vol.168
, Issue.8
, pp. 918-951
-
-
Gibson, R.L.1
Burns, J.L.2
Ramsey, B.W.3
-
7
-
-
0029875463
-
Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward
-
Döring G, Jansen S, Noll H, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol. 1996;21(2):90-100.
-
(1996)
Pediatr Pulmonol
, vol.21
, Issue.2
, pp. 90-100
-
-
Döring, G.1
Jansen, S.2
Noll, H.3
-
8
-
-
9644295892
-
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from 1992 Jan through 2004 Jun, issued 2004 Oct
-
National Nosocomial Infections Surveillance System
-
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from 1992 Jan through 2004 Jun, issued 2004 Oct. Am J Infect Control. 2004;32(8):470-485.
-
(2004)
Am J Infect Control
, vol.32
, Issue.8
, pp. 470-485
-
-
-
9
-
-
12844270608
-
Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
-
Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-588.
-
(2005)
JAMA
, vol.293
, Issue.5
, pp. 581-588
-
-
Li, Z.1
Kosorok, M.R.2
Farrell, P.M.3
-
10
-
-
0031873820
-
Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis
-
Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998;26(2):81-88.
-
(1998)
Pediatr Pulmonol
, vol.26
, Issue.2
, pp. 81-88
-
-
Kosorok, M.R.1
Jalaluddin, M.2
Farrell, P.M.3
-
11
-
-
0030850089
-
Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings
-
Renders NH, Sijmons MA, van Belkum A, Overbeek SE, Mouton JW, Verbrugh HA. Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol. 1997;148(5):447-454.
-
(1997)
Res Microbiol
, vol.148
, Issue.5
, pp. 447-454
-
-
Renders, N.H.1
Sijmons, M.A.2
van Belkum, A.3
Overbeek, S.E.4
Mouton, J.W.5
Verbrugh, H.A.6
-
13
-
-
34248658815
-
Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection
-
Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2007;2:153-164.
-
(2007)
Future Microbiol
, vol.2
, pp. 153-164
-
-
Govan, J.R.1
Brown, A.R.2
Jones, A.M.3
-
14
-
-
33744814106
-
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
-
Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006;103(22):8487-8492.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, Issue.22
, pp. 8487-8492
-
-
Smith, E.E.1
Buckley, D.G.2
Wu, Z.3
-
15
-
-
17144382063
-
Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis
-
Ramsey DM, Wozniak DJ. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol. 2005; 56(2):309-322.
-
(2005)
Mol Microbiol
, vol.56
, Issue.2
, pp. 309-322
-
-
Ramsey, D.M.1
Wozniak, D.J.2
-
16
-
-
0141650541
-
Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection
-
Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol. 2003;52(Pt 9):731-740.
-
(2003)
J Med Microbiol
, vol.52
, Issue.PART 9
, pp. 731-740
-
-
Song, Z.1
Wu, H.2
Ciofu, O.3
-
17
-
-
0029814366
-
Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia
-
Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60(3):539-574.
-
(1996)
Microbiol Rev
, vol.60
, Issue.3
, pp. 539-574
-
-
Govan, J.R.1
Deretic, V.2
-
18
-
-
0035353081
-
Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and clinical significance
-
Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem. 2001;1(1):59-71.
-
(2001)
Curr Top Med Chem
, vol.1
, Issue.1
, pp. 59-71
-
-
Poole, K.1
Srikumar, R.2
-
19
-
-
0027494050
-
Multiple antibiotic resistance in Pseudomonas aeruginosa: Evidence for involvement of an efflux operon
-
Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol. 1993;175(22):7363-7372.
-
(1993)
J Bacteriol
, vol.175
, Issue.22
, pp. 7363-7372
-
-
Poole, K.1
Krebes, K.2
McNally, C.3
Neshat, S.4
-
20
-
-
0042769424
-
Ambler class A extendedspectrum beta-lactamases in Pseudomonas aeruginosa: Novel developments and clinical impact
-
Weldhagen GF, Poirel L, Nordmann P. Ambler class A extendedspectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003;47(8):2385-2392.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, Issue.8
, pp. 2385-2392
-
-
Weldhagen, G.F.1
Poirel, L.2
Nordmann, P.3
-
21
-
-
0018377101
-
The chest roentgenogram in cystic fibrosis: A new scoring system
-
Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics. 1979;63(1): 24-29.
-
(1979)
Pediatrics
, vol.63
, Issue.1
, pp. 24-29
-
-
Brasfield, D.1
Hicks, G.2
Soong, S.3
Tiller, R.E.4
-
22
-
-
0027535889
-
Wisconsin cystic fibrosis chest radiograph scoring system
-
Weatherly MR, Palmer CG, Peters ME, et al. Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics. 1993;91(2): 488-495.
-
(1993)
Pediatrics
, vol.91
, Issue.2
, pp. 488-495
-
-
Weatherly, M.R.1
Palmer, C.G.2
Peters, M.E.3
-
23
-
-
0030790441
-
High- resolution CT in the acute exacerbation of cystic fibrosis: Evaluation of acute findings, reversibility of those findings, and clinical correlation
-
Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High- resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol. 1997;169(2):375-380.
-
(1997)
AJR Am J Roentgenol
, vol.169
, Issue.2
, pp. 375-380
-
-
Shah, R.M.1
Sexauer, W.2
Ostrum, B.J.3
Fiel, S.B.4
Friedman, A.C.5
-
24
-
-
0033006235
-
Evolution of CT findings in patients with cystic fibrosis
-
Helbich TH, Heinz-Peer G, Fleischmann D, et al. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol. 1999;173(1):81-88.
-
(1999)
AJR Am J Roentgenol
, vol.173
, Issue.1
, pp. 81-88
-
-
Helbich, T.H.1
Heinz-Peer, G.2
Fleischmann, D.3
-
25
-
-
0031949095
-
Cystic fibrosis: When should highresolution computed tomography of the chest be obtained?
-
Santamaria F, Grillo G, Guidi G, et al. Cystic fibrosis: when should highresolution computed tomography of the chest be obtained? Pediatrics. 1998;101(5):908-913.
-
(1998)
Pediatrics
, vol.101
, Issue.5
, pp. 908-913
-
-
Santamaria, F.1
Grillo, G.2
Guidi, G.3
-
26
-
-
0020585150
-
Changes in the normal maximal expiratory flow-volume curve with growth and aging
-
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127(6):725-734.
-
(1983)
Am Rev Respir Dis
, vol.127
, Issue.6
, pp. 725-734
-
-
Knudson, R.J.1
Lebowitz, M.D.2
Holberg, C.J.3
Burrows, B.4
-
27
-
-
0020525824
-
Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age
-
Dockery DW, Berkey CS, Ware JH, Speizer FE, Ferris BG Jr. Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age. Am Rev Respir Dis. 1983;128(3):405-412.
-
(1983)
Am Rev Respir Dis
, vol.128
, Issue.3
, pp. 405-412
-
-
Dockery, D.W.1
Berkey, C.S.2
Ware, J.H.3
Speizer, F.E.4
Ferris Jr, B.G.5
-
28
-
-
0026520359
-
Prediction of mortality in patients with cystic f ibrosis
-
Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic f ibrosis. N Engl J Med. 1992;326(18):1187-1191.
-
(1992)
N Engl J Med
, vol.326
, Issue.18
, pp. 1187-1191
-
-
Kerem, E.1
Reisman, J.2
Corey, M.3
Canny, G.J.4
Levison, H.5
-
29
-
-
0033531143
-
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.Cystic Fibrosis Inhaled Tobramycin Study Group
-
Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30.
-
(1999)
N Engl J Med
, vol.340
, Issue.1
, pp. 23-30
-
-
Ramsey, B.W.1
Pepe, M.S.2
Quan, J.M.3
-
30
-
-
0032718969
-
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis
-
Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321-328.
-
(1999)
Pediatr Pulmonol
, vol.28
, Issue.5
, pp. 321-328
-
-
Rosenfeld, M.1
Emerson, J.2
Accurso, F.3
-
31
-
-
0030001433
-
Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis
-
Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267-275.
-
(1996)
Pediatr Pulmonol
, vol.21
, Issue.5
, pp. 267-275
-
-
Armstrong, D.S.1
Grimwood, K.2
Carlin, J.B.3
Carzino, R.4
Olinsky, A.5
Phelan, P.D.6
-
32
-
-
0035060298
-
Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis
-
Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax. 2001;56(4):306-311.
-
(2001)
Thorax
, vol.56
, Issue.4
, pp. 306-311
-
-
Henig, N.R.1
Tonelli, M.R.2
Pier, M.V.3
Burns, J.L.4
Aitken, M.L.5
-
33
-
-
0042922372
-
Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis
-
Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 2003;41(9):4009-4015.
-
(2003)
J Clin Microbiol
, vol.41
, Issue.9
, pp. 4009-4015
-
-
Miller, M.B.1
Gilligan, P.H.2
-
34
-
-
23844474727
-
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients
-
Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9): 690-703.
-
(2005)
Clin Microbiol Infect
, vol.11
, Issue.9
, pp. 690-703
-
-
Cantón, R.1
Cobos, N.2
de Gracia, J.3
-
35
-
-
0034016422
-
Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
-
Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2000;38(5):1818-1822.
-
(2000)
J Clin Microbiol
, vol.38
, Issue.5
, pp. 1818-1822
-
-
Burns, J.L.1
Saiman, L.2
Whittier, S.3
-
36
-
-
0032804197
-
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis
-
Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA, Jones RN. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol. 1999;37(9):2987-2991.
-
(1999)
J Clin Microbiol
, vol.37
, Issue.9
, pp. 2987-2991
-
-
Saiman, L.1
Burns, J.L.2
Whittier, S.3
Krzewinski, J.4
Marshall, S.A.5
Jones, R.N.6
-
37
-
-
0034821607
-
Defining a pulmonary exacerbation in cystic fibrosis
-
Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359-365.
-
(2001)
J Pediatr
, vol.139
, Issue.3
, pp. 359-365
-
-
Rosenfeld, M.1
Emerson, J.2
Williams-Warren, J.3
-
38
-
-
0032433579
-
Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis.Current practice and suggestions for future directions
-
Touw DJ, Vinks AA, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet. 1998;35(6):437-459.
-
(1998)
Clin Pharmacokinet
, vol.35
, Issue.6
, pp. 437-459
-
-
Touw, D.J.1
Vinks, A.A.2
Mouton, J.W.3
Horrevorts, A.M.4
-
39
-
-
0023628218
-
Antibiotic pharmacokinetics in cystic fibrosis.Differences and clinical significance
-
De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet. 1987;13(4):228-253.
-
(1987)
Clin Pharmacokinet
, vol.13
, Issue.4
, pp. 228-253
-
-
de Groot, R.1
Smith, A.L.2
-
40
-
-
70350593962
-
Update on antibiotics for infection control in cystic fibrosis
-
Kirkby S, Novak K, McCoy K. Update on antibiotics for infection control in cystic fibrosis. Expert Rev Anti Infect Ther. 2009;7(8):967-980.
-
(2009)
Expert Rev Anti Infect Ther
, vol.7
, Issue.8
, pp. 967-980
-
-
Kirkby, S.1
Novak, K.2
McCoy, K.3
-
41
-
-
0030664021
-
Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis
-
Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112(5):1208-1213.
-
(1997)
Chest
, vol.112
, Issue.5
, pp. 1208-1213
-
-
Bates, R.D.1
Nahata, M.C.2
Jones, J.W.3
-
42
-
-
13844254908
-
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: A randomised controlled trial
-
Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573-578.
-
(2005)
Lancet
, vol.365
, Issue.9459
, pp. 573-578
-
-
Smyth, A.1
Tan, K.H.2
Hyman-Taylor, P.3
-
43
-
-
77950899558
-
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
-
CD002009
-
Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2010;(1):CD002009.
-
(2010)
Cochrane Database Syst Rev.
, vol.1
-
-
Smyth, A.R.1
Bhatt, J.2
-
44
-
-
0142105983
-
Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management
-
Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med. 2003;9(6):492-497.
-
(2003)
Curr Opin Pulm Med
, vol.9
, Issue.6
, pp. 492-497
-
-
Rosenfeld, M.1
Ramsey, B.W.2
Gibson, R.L.3
-
45
-
-
0025868478
-
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
-
Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-726.
-
(1991)
Lancet
, vol.338
, Issue.8769
, pp. 725-726
-
-
Valerius, N.H.1
Koch, C.2
Høiby, N.3
-
46
-
-
0030995361
-
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
-
Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330-335.
-
(1997)
Pediatr Pulmonol
, vol.23
, Issue.5
, pp. 330-335
-
-
Frederiksen, B.1
Koch, C.2
Høiby, N.3
-
47
-
-
77955413607
-
Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis
-
Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev. 2010;11(3):177-184.
-
(2010)
Paediatr Respir Rev
, vol.11
, Issue.3
, pp. 177-184
-
-
Stuart, B.1
Lin, J.H.2
Mogayzel Jr, P.J.3
-
48
-
-
77950126962
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
-
CD004197
-
Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4):CD004197.
-
(2009)
Cochrane Database Syst Rev
, vol.4
-
-
Langton Hewer, S.C.1
Smyth, A.R.2
-
49
-
-
0037445216
-
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
-
Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841-849.
-
(2003)
Am J Respir Crit Care Med
, vol.167
, Issue.6
, pp. 841-849
-
-
Gibson, R.L.1
Emerson, J.2
McNamara, S.3
-
50
-
-
59649123905
-
Acquisition and eradication of P.aeruginosa in young children with cystic fibrosis
-
Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009;33(2):305-311.
-
(2009)
Eur Respir J
, vol.33
, Issue.2
, pp. 305-311
-
-
Douglas, T.A.1
Brennan, S.2
Gard, S.3
-
51
-
-
77957874451
-
Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: Is susceptibility testing justified?
-
Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother. 2010;65(11):2373-2375.
-
(2010)
J Antimicrob Chemother
, vol.65
, Issue.11
, pp. 2373-2375
-
-
Macdonald, D.1
Cuthbertson, L.2
Doherty, C.3
-
52
-
-
0036157901
-
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
-
Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55-63.
-
(2002)
Chest
, vol.121
, Issue.1
, pp. 55-63
-
-
Moss, R.B.1
-
53
-
-
36248953255
-
Cystic f ibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
-
Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic f ibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-969.
-
(2007)
Am J Respir Crit Care Med
, vol.176
, Issue.10
, pp. 957-969
-
-
Flume, P.A.1
O'Sullivan, B.P.2
Robinson, K.A.3
-
54
-
-
0036736583
-
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
-
Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-664.
-
(2002)
Eur Respir J
, vol.20
, Issue.3
, pp. 658-664
-
-
Hodson, M.E.1
Gallagher, C.G.2
Govan, J.R.3
-
56
-
-
0034835277
-
Microbiological and immunologic considerations with aerosolized drug delivery
-
LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001;120(3 Suppl):118S-123S.
-
(2001)
Chest
, vol.120
, Issue.3 SUPPL.
, pp. 118-123
-
-
Lipuma, J.J.1
-
57
-
-
0029958486
-
Pharmacokinetics of inhaled drugs
-
Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697-705.
-
(1996)
Br J Clin Pharmacol
, vol.42
, Issue.6
, pp. 697-705
-
-
Lipworth, B.J.1
-
58
-
-
4444256217
-
Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients
-
Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother. 2004;54(2):508-514.
-
(2004)
J Antimicrob Chemother
, vol.54
, Issue.2
, pp. 508-514
-
-
Badia, J.R.1
Soy, D.2
Adrover, M.3
-
59
-
-
77953877127
-
Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis
-
Guy EL, Bosomworth M, Denton M, Conway SP, Brownlee KG, Lee TW. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. J Cyst Fibros. 2010;9(4):292-295.
-
(2010)
J Cyst Fibros
, vol.9
, Issue.4
, pp. 292-295
-
-
Guy, E.L.1
Bosomworth, M.2
Denton, M.3
Conway, S.P.4
Brownlee, K.G.5
Lee, T.W.6
-
60
-
-
77951642713
-
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
-
Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13(6):R200.
-
(2009)
Crit Care
, vol.13
, Issue.6
-
-
Luyt, C.E.1
Clavel, M.2
Guntupalli, K.3
-
61
-
-
0347812929
-
Aerosolized antibiotics in cystic fibrosis
-
Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med. 2003;24(6):717-726.
-
(2003)
Semin Respir Crit Care Med
, vol.24
, Issue.6
, pp. 717-726
-
-
Sexauer, W.P.1
Fiel, S.B.2
-
62
-
-
55549137086
-
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis
-
McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-928.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.9
, pp. 921-928
-
-
McCoy, K.S.1
Quittner, A.L.2
Oermann, C.M.3
Gibson, R.L.4
Retsch-Bogart, G.Z.5
Montgomery, A.B.6
-
63
-
-
65949124667
-
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
-
Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.
-
(2009)
Chest
, vol.135
, Issue.5
, pp. 1223-1232
-
-
Retsch-Bogart, G.Z.1
Quittner, A.L.2
Gibson, R.L.3
-
64
-
-
78349232036
-
Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
-
Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010;202(10):1585-1592.
-
(2010)
J Infect Dis
, vol.202
, Issue.10
, pp. 1585-1592
-
-
Herrmann, G.1
Yang, L.2
Wu, H.3
-
65
-
-
0024267448
-
Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
-
Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol. 1988;28(8):691-699.
-
(1988)
J Clin Pharmacol
, vol.28
, Issue.8
, pp. 691-699
-
-
Reed, M.D.1
Stern, R.C.2
Myers, C.M.3
Yamashita, T.S.4
Blumer, J.L.5
-
66
-
-
0025633092
-
Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: Clinical significance and therapeutic approaches
-
Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother. 1990;26 Suppl F: 165-179.
-
(1990)
J Antimicrob Chemother
, vol.26
, Issue.SUPPL. F
, pp. 165-179
-
-
Ball, P.1
-
67
-
-
0141816759
-
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial
-
Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756.
-
(2003)
JAMA
, vol.290
, Issue.13
, pp. 1749-1756
-
-
Saiman, L.1
Marshall, B.C.2
Mayer-Hamblett, N.3
-
68
-
-
0036188534
-
Macrolide antibiotics and cystic fibrosis
-
Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax. 2002;57(3):189-190.
-
(2002)
Thorax
, vol.57
, Issue.3
, pp. 189-190
-
-
Peckham, D.G.1
-
69
-
-
33750078400
-
Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells
-
Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977-982.
-
(2006)
Biochem Biophys Res Commun
, vol.350
, Issue.4
, pp. 977-982
-
-
Cigana, C.1
Nicolis, E.2
Pasetto, M.3
Assael, B.M.4
Melotti, P.5
-
70
-
-
33751177801
-
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice
-
Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res. 2006;7:134.
-
(2006)
Respir Res
, vol.7
, pp. 134
-
-
Legssyer, R.1
Huaux, F.2
Lebacq, J.3
-
72
-
-
8644251326
-
Azithromycin for cystic fibrosis
-
Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J. 2004;24(5):834-838.
-
(2004)
Eur Respir J
, vol.24
, Issue.5
, pp. 834-838
-
-
Southern, K.W.1
Barker, P.M.2
-
73
-
-
0037190575
-
Long term azithromycin in children with cystic fibrosis: A randomised, placebo- controlled crossover trial
-
Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo- controlled crossover trial. Lancet. 2002;360(9338):978-984.
-
(2002)
Lancet
, vol.360
, Issue.9338
, pp. 978-984
-
-
Equi, A.1
Balfour-Lynn, I.M.2
Bush, A.3
Rosenthal, M.4
-
74
-
-
0025230752
-
Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
-
Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141(4 Pt 1): 914-921.
-
(1990)
Am Rev Respir Dis
, vol.141
, Issue.4 PART 1
, pp. 914-921
-
-
Regelmann, W.E.1
Elliott, G.R.2
Warwick, W.J.3
Clawson, C.C.4
-
75
-
-
0029934215
-
Management of pulmonary disease in patients with cystic fibrosis
-
Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335(3):179-188.
-
(1996)
N Engl J Med
, vol.335
, Issue.3
, pp. 179-188
-
-
Ramsey, B.W.1
-
76
-
-
0033498208
-
Comparison of a beta- lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
-
Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta- lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999;134(4):413-421.
-
(1999)
J Pediatr
, vol.134
, Issue.4
, pp. 413-421
-
-
Smith, A.L.1
Doershuk, C.2
Goldmann, D.3
-
77
-
-
70350446684
-
Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations
-
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.
-
(2009)
Am J Respir Crit Care Med
, vol.180
, Issue.9
, pp. 802-808
-
-
Flume, P.A.1
Mogayzel Jr, P.J.2
Robinson, K.A.3
-
78
-
-
10344219968
-
Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
-
Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39(1):15-20.
-
(2005)
Pediatr Pulmonol
, vol.39
, Issue.1
, pp. 15-20
-
-
Al-Aloul, M.1
Miller, H.2
Alapati, S.3
Stockton, P.A.4
Ledson, M.J.5
Walshaw, M.J.6
-
79
-
-
21844443142
-
Single versus combination intravenous antibiotic therapy for people with cystic fibrosis
-
CD002007
-
Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2005;2:CD002007.
-
(2005)
Cochrane Database Syst Rev
, vol.2
-
-
Elphick, H.E.1
Tan, A.2
-
80
-
-
44949111525
-
Duration of intravenous antibiotic therapy in people with cystic fibrosis
-
CD006682
-
Fernandes B, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2008;2:CD006682.
-
(2008)
Cochrane Database Syst Rev
, vol.2
-
-
Fernandes, B.1
Plummer, A.2
Wildman, M.3
-
81
-
-
0030935245
-
Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects
-
Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997;10(4):896-900.
-
(1997)
Eur Respir J
, vol.10
, Issue.4
, pp. 896-900
-
-
Wolter, J.M.1
Bowler, S.D.2
Nolan, P.J.3
McCormack, J.G.4
-
83
-
-
0029198302
-
Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross-over randomized study
-
Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study. Pediatr Pulmonol. 1995;19(1):16-22.
-
(1995)
Pediatr Pulmonol
, vol.19
, Issue.1
, pp. 16-22
-
-
Braggion, C.1
Cappelletti, L.M.2
Cornacchia, M.3
Zanolla, L.4
Mastella, G.5
-
84
-
-
32044445488
-
Microbiology of Airway Disease In a Cohort of Patients With Cystic Fibrosis
-
Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis. 2006;6:4.
-
(2006)
BMC Infect Dis
, vol.6
, Issue.4
-
-
Lambiase, A.1
Raia, V.2
del Pezzo, M.3
Sepe, A.4
Carnovale, V.5
Rossano, F.6
-
85
-
-
34548048797
-
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
-
Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2): 562-568.
-
(2007)
Chest
, vol.132
, Issue.2
, pp. 562-568
-
-
Merlo, C.A.1
Boyle, M.P.2
Diener-West, M.3
Marshall, B.C.4
Goss, C.H.5
Lechtzin, N.6
-
86
-
-
33644508050
-
Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa
-
Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27-33.
-
(2006)
Respiration
, vol.73
, Issue.1
, pp. 27-33
-
-
Lechtzin, N.1
John, M.2
Irizarry, R.3
Merlo, C.4
Diette, G.B.5
Boyle, M.P.6
-
87
-
-
33745910567
-
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature
-
Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4(2):138-146.
-
(2006)
Clin Med Res
, vol.4
, Issue.2
, pp. 138-146
-
-
Falagas, M.E.1
Kasiakou, S.K.2
Tsiodras, S.3
Michalopoulos, A.4
-
88
-
-
0002088906
-
The properties and mode of action of the polymyxins
-
Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev. 1956;20(1):14-27.
-
(1956)
Bacteriol Rev
, vol.20
, Issue.1
, pp. 14-27
-
-
Newton, B.A.1
-
89
-
-
0035171243
-
Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines
-
Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001;39(1):183-190.
-
(2001)
J Clin Microbiol
, vol.39
, Issue.1
, pp. 183-190
-
-
Gales, A.C.1
Reis, A.O.2
Jones, R.N.3
-
90
-
-
0035118424
-
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
-
Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45(3):781-785.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, Issue.3
, pp. 781-785
-
-
Li, J.1
Turnidge, J.2
Milne, R.3
Nation, R.L.4
Coulthard, K.5
-
91
-
-
17644389620
-
Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
-
Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-1341.
-
(2005)
Clin Infect Dis
, vol.40
, Issue.9
, pp. 1333-1341
-
-
Falagas, M.E.1
Kasiakou, S.K.2
-
92
-
-
34447560960
-
Toxicity of polymyxins: A systematic review of the evidence from old and recent studies
-
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
-
(2006)
Crit Care
, vol.10
, Issue.1
-
-
Falagas, M.E.1
Kasiakou, S.K.2
-
93
-
-
77955627319
-
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management
-
Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother. 2010;65(9):1853-1861.
-
(2010)
J Antimicrob Chemother
, vol.65
, Issue.9
, pp. 1853-1861
-
-
Parkins, M.D.1
Elborn, J.S.2
-
94
-
-
67749135403
-
In vitro activity of doripenem
-
Sahm D. In vitro activity of doripenem. Clin Infect Dis. 2009; 49 Suppl 1:S11-S16
-
(2009)
Clin Infect Dis
, vol.49
, Issue.SUPPL. 1
-
-
Sahm, D.1
-
95
-
-
34248334196
-
Comparative review of the carbapenems
-
Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-1052.
-
(2007)
Drugs
, vol.67
, Issue.7
, pp. 1027-1052
-
-
Zhanel, G.G.1
Wiebe, R.2
Dilay, L.3
-
96
-
-
67650470947
-
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers
-
Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009;49(7):798-806.
-
(2009)
J Clin Pharmacol
, vol.49
, Issue.7
, pp. 798-806
-
-
Cirillo, I.1
Vaccaro, N.2
Turner, K.3
Solanki, B.4
Natarajan, J.5
Redman, R.6
-
97
-
-
41649099025
-
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
-
Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36(4):1089-1096.
-
(2008)
Crit Care Med
, vol.36
, Issue.4
, pp. 1089-1096
-
-
Chastre, J.1
Wunderink, R.2
Prokocimer, P.3
Lee, M.4
Kaniga, K.5
Friedland, I.6
-
98
-
-
45749156804
-
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study
-
Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study. J Antimicrob Chemother. 2008;62(1):206-208.
-
(2008)
J Antimicrob Chemother
, vol.62
, Issue.1
, pp. 206-208
-
-
Walkty, A.1
Decorby, M.2
Nichol, K.3
Karlowsky, J.A.4
Hoban, D.J.5
Zhanel, G.G.6
-
99
-
-
44949113364
-
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
-
CD006961
-
Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;3:CD006961.
-
(2008)
Cochrane Database Syst Rev
, vol.3
-
-
Waters, V.1
Ratjen, F.2
-
100
-
-
34548833833
-
Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms
-
Aaron SD. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev. 2007;8(3):256-261.
-
(2007)
Paediatr Respir Rev
, vol.8
, Issue.3
, pp. 256-261
-
-
Aaron, S.D.1
-
101
-
-
0034820682
-
Pseudomonas vaccination and immunotherapy: An overview
-
Holder IA. Pseudomonas vaccination and immunotherapy: an overview. J Burn Care Rehabil. 2001;22(5):311-320.
-
(2001)
J Burn Care Rehabil
, vol.22
, Issue.5
, pp. 311-320
-
-
Holder, I.A.1
-
102
-
-
3042638668
-
Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection
-
Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J. 2004;23(6):504-510.
-
(2004)
Pediatr Infect Dis J
, vol.23
, Issue.6
, pp. 504-510
-
-
Lang, A.B.1
Rüdeberg, A.2
Schöni, M.H.3
Que, J.U.4
Fürer, E.5
Schaad, U.B.6
-
103
-
-
55049131107
-
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
-
CD001399
-
Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;4:CD001399.
-
(2008)
Cochrane Database Syst Rev
, vol.4
-
-
Johansen, H.K.1
Gøtzsche, P.C.2
-
104
-
-
0024805809
-
Biological role of different antibody classes
-
Spiegelberg HL. Biological role of different antibody classes. Int Arch Allergy Appl Immunol. 1989;90 Suppl 1:22-27.
-
(1989)
Int Arch Allergy Appl Immunol
, vol.90
, Issue.SUPPL. 1
, pp. 22-27
-
-
Spiegelberg, H.L.1
-
105
-
-
67749124368
-
Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers
-
Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009;53(8):3442-3446.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.8
, pp. 3442-3446
-
-
Lazar, H.1
Horn, M.P.2
Zuercher, A.W.3
-
107
-
-
34250169414
-
Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model
-
McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother. 2007;51(6):1934-1938.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, Issue.6
, pp. 1934-1938
-
-
McVay, C.S.1
Velásquez, M.2
Fralick, J.A.3
-
108
-
-
33846612678
-
Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice
-
Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51(2): 446-452.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, Issue.2
, pp. 446-452
-
-
Watanabe, R.1
Matsumoto, T.2
Sano, G.3
-
109
-
-
68349154135
-
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy
-
Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349-357.
-
(2009)
Clin Otolaryngol
, vol.34
, Issue.4
, pp. 349-357
-
-
Wright, A.1
Hawkins, C.H.2
Anggård, E.E.3
Harper, D.R.4
-
110
-
-
67650446165
-
Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies
-
Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med. 2009;37(5):1777-1786.
-
(2009)
Crit Care Med
, vol.37
, Issue.5
, pp. 1777-1786
-
-
Veesenmeyer, J.L.1
Hauser, A.R.2
Lisboa, T.3
Rello, J.4
|